header-logo header-logo

Home Login E-newsletter About us
02 October 2014
Issue: 7624 / Categories: Case law , Law digest
printer mail-detail

Patent—Validity

© Copyright LexisNexis 2026. All Rights Reserved.

Teva UK Ltd and another v Astrazeneca AB [2014] EWHC 2873 (Pat), [2014] All ER (D) 44 (Sep)

The Patents Court considered challenges to the legitimacy of a patent for a treatment of asthma. It held that a challenge to the patent based on anticipation would be dismissed. However, a challenge to the patent on grounds of obviousness was made out and the patent was therefore invalid. A number of amended claims put forward by the owner of the patent would be rejected.

If you are not a subscriber, subscribe now to read this content
If you are already a subscriber sign in
...or Register for two weeks' free access to subscriber content

MOVERS & SHAKERS

Read All
Sponsored by
Walkers—Muriel Marseille

Walkers—Muriel Marseille

Ashurst's Chief Risk Officer joins Walkers

Excello Law—John Osborne

Excello Law—John Osborne

Northern family lawyer John Osborne joins Excello

mfg Solicitors—Rebecca Rogers, Kennedy Langley & Victoria Griffiths

mfg Solicitors—Rebecca Rogers, Kennedy Langley & Victoria Griffiths

Trio of promotions announced at Kidderminster law firm mfg Solicitors

NEWS
Read All
NLJ this week: Company conspiracy clarified
A sole director can conspire with their own company for the purposes of the tort of unlawful means conspiracy, the High Court has ruled in a judgment with potentially wide implications for business disputes
NLJ this week: Home is where intent lies
The Court of Appeal has reinforced that domicile depends on intention rather than residence alone, in a significant post-Brexit ruling on cross-border financial remedy claims
NLJ this week: Farewell to Chancery
The Chancery Division's long history comes to an end this autumn as it is reborn as the Business and Property Division, prompting questions over whether the shake-up is really necessary
NLJ this week: Silence carries a price
The Financial Conduct Authority (FCA) continues to show that failing to disclose regulatory issues can attract harsher consequences than the original misconduct itself
NLJ this week: Costs sting after a courtroom gamble
Rejecting a generous settlement can prove an expensive mistake, as two recent high-profile cases demonstrate
Copyright © 2026 LexisNexis
back-to-top-scroll